Provided by Tiger Trade Technology Pte. Ltd.

Eton Pharmaceuticals, Inc.

14.76
+0.41002.86%
Post-market: 14.760.00000.00%17:43 EST
Volume:228.80K
Turnover:3.38M
Market Cap:395.83M
PE:-57.04
High:15.01
Open:14.60
Low:14.52
Close:14.35
52wk High:23.00
52wk Low:11.09
Shares:26.82M
Float Shares:18.14M
Volume Ratio:1.00
T/O Rate:1.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2588
EPS(LYR):-0.1476
ROE:-34.17%
ROA:1.25%
PB:17.12
PE(LYR):-99.98

Loading ...

Eton licenses U.S. marketing rights to ultra-rare disease product candidate

TIPRANKS
·
Feb 02

Eton Pharmaceuticals Plans 2026 Launch of FDA-Reviewed Ultra-Rare Disease Product, Expands Pipeline and Pursues Additional High-Value Opportunities

Reuters
·
Feb 02

Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate

THOMSON REUTERS
·
Feb 02

Eton Pharmaceuticals Inc - Potential Approval and Launch Mid-2026

THOMSON REUTERS
·
Feb 02

Highlighting December 2025's Growth Leaders With Insider Ownership

Simply Wall St.
·
Dec 16, 2025

Eton Pharmaceuticals Issues Amended Financial Report on Acquired Increlex Product

Reuters
·
Nov 19, 2025

Eton Pharmaceuticals Q3 2025 Earnings Call Summary and Q&A Highlights: Record Revenue Growth and Strategic Expansion

Earnings Call
·
Nov 09, 2025

Eton Pharma (ETON) Q3 2025 Earnings Transcript

Motley Fool Transcribing
·
Nov 09, 2025

Eton Pharmaceuticals Q3 Adj. EPS $0.04 Misses $0.09 Estimate, Sales $22.459M Beat $20.474M Estimate

Benzinga
·
Nov 07, 2025

BRIEF-Eton Pharmaceuticals Q3 Net Income USD -1.927 Million

Reuters
·
Nov 07, 2025

Eton Pharmaceuticals Q3 Adjusted EPS USD 0.04

THOMSON REUTERS
·
Nov 07, 2025

Eton Pharmaceuticals Q3 EPS USD -0.07

THOMSON REUTERS
·
Nov 07, 2025

3 Growth Companies With Insider Ownership Up To 31%

Simply Wall St.
·
Oct 30, 2025

CFO James R. Gruber Reports Disposal of Common Shares of Eton Pharmaceuticals Inc

Reuters
·
Aug 21, 2025

Eton Pharmaceuticals Q2 Net Income USD -2.585 Million

Reuters
·
Aug 08, 2025

Eton Pharmaceuticals Q2 Adj. EPS $(0.10) Misses $(0.05) Estimate, Sales $18.93M Beat $16.60M Estimate

Benzinga
·
Aug 08, 2025

Eton Pharmaceuticals Inc - Projects $80 Mln Annual Revenue Run Rate in Q3

THOMSON REUTERS
·
Aug 08, 2025

Eton Pharmaceuticals Inc Q2 REV View $16.7 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
Aug 08, 2025

Eton Pharmaceuticals Q2 Revenue USD 18.9 Million

THOMSON REUTERS
·
Aug 08, 2025